• About Us
  • Contact Us
  • Photo Gallery
  • Privacy Policy
  • Terms of Use
  • Citi TV
Wednesday, September 27, 2023
Citinewsroom - Comprehensive News in Ghana
  • Home
  • News
  • Business
  • Sports
  • Showbiz
  • Opinion
  • Infographics
  • Listen To CitiFM
  • Videos
No Result
View All Result
Citinewsroom - Comprehensive News in Ghana
  • Home
  • News
  • Business
  • Sports
  • Showbiz
  • Opinion
  • Infographics
  • Listen To CitiFM
  • Videos
No Result
View All Result
Citinewsroom - Comprehensive News in Ghana
No Result
View All Result

India orders 300 million unapproved COVID-19 jabs

June 4, 2021
ShareShareShareShare

India has ordered 300 million doses of an unapproved coronavirus vaccine amid a devastating second wave.

The unnamed vaccine from Indian firm Biological E is in Phase 3 trials, and had showed “promising results” in the first two phases, the federal government said in a statement.

The $206m order is the first India has signed for a jab that has not received emergency approval.

This comes as the country struggles to speed up its lagging vaccine drive.

India has administered just over 220 million jabs so far although much of its 1.4 billion population is now eligible for the vaccine. Less than 10% of the country has received at least one dose of the vaccination, largely because of a severe shortage of doses.

Although COVID-19 case numbers have been dropping, India is still adding more than 100,000 news cases a day. It has recorded more than 340,000 deaths from the virus so far, but experts say the number is vastly underestimated.

India’s federal government, led by Prime Minister Narendra Modi, has been criticized for not placing huge orders ahead of time with either Indian or foreign vaccine makers.

India is currently giving three vaccines – Covishield, manufactured by the Serum Institute of India (SII), and Covaxin, developed by Indian firm Bharat Biotech and the government’s Indian Council of Medical Research, and Sputnik V, which is developed by Moscow’s Gamaleya Institute.

Compared to the single order from Biological E for 300 million doses, India brought about 350 million doses from both Covishield and Covaxin between January and May.

India’s drug regulator gave Covaxin emergency approval in January before trials were completed – data on its efficacy is yet to be released.

The new vaccine from Biological E is “likely to be available in the next few months,” according to the government.

Mr. Modi’s government is racing to shore up its vaccine stocks as COVID-19 numbers dip, hoping to be well-prepared for what experts say is an inevitable third wave.

India’s vaccine drive, which had a promising start in January, began to slow down because vaccine hesitancy crept in as cases dropped. But numbers soon rose again in a deadly second wave that saw hospitals falling short of beds and crematoriums running short of space.

Hoping to stem the tide, the government threw open the drive in May to everyone above the age of 18 but India’s two vaccine makers – Serum Institute and Bharat Biotech – could not guarantee supply at that scale.

But shortages persist and have also led to vast inequalities in access with rural areas, the poor and women falling behind in the line for jabs.

Source: BBC
Tags: COVID-19Indiajabs
Previous Post

Netanyahu seeks block on deal to oust him

Next Post

Parents and wards stranded at KNUST Basic Sch. over Universities’ Senior Staff strike

Next Post

Parents and wards stranded at KNUST Basic Sch. over Universities' Senior Staff strike

Strike by Universities' Senior Staff Assoc. intensify as more departments join

Let's build consensus to develop Ghana; time is ticking fast - Mahama

TOP STORIES

Don’t be distracted, stay focused on breaking the 8 – Bawumia tells NPP

September 27, 2023

Ghanaians lament as Korle-Bu increases cost of dialysis

September 27, 2023

It’s unfair for high-profile criminal cases to drag for years – Dame laments

September 27, 2023
Load More
ADVERTISEMENT
Citinewsroom - Comprehensive News in Ghana

CitiNewsroom.com is Ghana's leading news website that delivers high quality innovative, alternative news that challenges the status quo.

Archives

Download App

Download

Download

  • About Us
  • Contact Us
  • Photo Gallery
  • Privacy Policy
  • Terms of Use
  • Citi TV

© 2023 All Rights Reserved Citi Newsroom.

No Result
View All Result
  • Home
  • News
  • Business
  • Sports
  • Showbiz
  • Opinion
  • Infographics
  • Listen To CitiFM
  • Videos

© 2023 All Rights Reserved Citi Newsroom.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT